Leaked data from Moderna and Merck's highly anticipated melanoma vaccine trial has led to a rare disconnect between doctors, who celebrated the result, and Wall Street, which sold off the stocks. Normally results of such pivotal drug studies are binary, with doctors, patients…
MRK Merck & Co., Inc.
XNYS
145.25
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
MRK
$145.25
—
Key stats
$145.25
- 52-Week Range
- $82.01 – $156.92
- YTD
- +36.45%
- IV Rank (30D)
- 66.88
- Straddle Price
- $11.27
- P/C Vol Ratio
- 0.49
- Market Cap
- $363.3B
- Open
- $145.02
- Day Range
- $143.41 – $145.44
- Volume
- 8,381,398
- Prev Close
- $147.24
Fair Value
MODEL: LONG
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 5.12% |
| Beta vs SPY | 0.47 |
| Cost of Equity (CAPM) | 7.49% (VRP-adj) |
| WACC | 7.26% |
| Volatility Risk Premium | +26.5pp (IV − HV30) |
| Effective Tax Rate | 23.2% |
| Rev. Growth (YoY, DCF input) | +3.0% |
| DCF Horizon | 10 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.03 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $16.1B |
| Return on Equity (TTM) | 7.6% |
| Book / Price | 12.5% |
| Gross Margin (TTM) | 73.9% |
| FCF Margin (TTM) | 24.4% |
| Debt / Equity | 1.02 |
| Quality Score | 3/6 — normal (10y DCF) |
| Market-Implied Growth | +5.2% (reverse-DCF on current price) |
| SMA 50 | $146.45 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $145.37 |
| Bollinger Width / SMA20 | 5.3% (drives anchor stability) |
| Net Debt | $41.3B |
| Market Cap | $368B |
Peers used for multiples: ABBV, AMGN, BMY, GILD, JNJ, LLY, PFE, UNH
60-Day Conviction
55%
20-Day Fair Value
≈ by Nov 23, 2026
$146.65
α +0.9%
rank 12%
conviction
59%
40-Day Fair Value
≈ by Dec 22, 2026
$148.10
α +1.9%
rank 10%
conviction
62%
60-Day Fair Value
≈ by Jan 20, 2027
$147.55
α +1.6%
rank 14%
conviction
55%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | $126.52 | 17% | |
| DDM (Gordon) | $78.73 | 13% | |
| Peer P/E | $141.59 | 5% | median 38.6× · 7 peers |
| Peer EV/EBITDA | $128.80 | 5% | median 18.3× · 8 peers |
| Peer P/B | $140.14 | 5% | median 7.6× · 7 peers |
| Peer P/S | $169.18 | 5% | median 6.2× · 8 peers |
| Market Anchor (SMA50) | $146.45 | 33% | stability 100% (BB-width) |
| Options Expected (B-L 30d) | $148.75 | 17% | 47 strikes · skew +0.15 |
As of 2026-10-23 · updated
Related
About
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834) · industry map
- Exchange
- XNYS
- Market Cap
- $363.3B
- Employees
- 75,000
- List Date
- 1949-04-20
- CIK
- 0000310158
- Next Earnings
- 2026-10-29 (Pre-Market)
- EPS Forecast
- $2.12 (5 est.)
- Headquarters
- Rahway, NJ
- Homepage
- https://www.merck.com
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. In cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 53% of the company's 2025 sales were generated from US human health (pharmaceuticals and vaccines).
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | -4.80% | 6.00% | -3.36% | 6.66% | -0.35% | 3.59% | 1.29% |
| Feb | -6.13% | -6.52% | -0.69% | 0.61% | -7.56% | 9.22% | -1.84% |
| Mar | 6.51% | 7.48% | -0.24% | 3.93% | -3.64% | -0.92% | 2.19% |
| Apr | -3.36% | 6.19% | 6.06% | -1.35% | -2.20% | -9.65% | -0.72% |
| May | -0.12% | 5.00% | -5.10% | -2.53% | -7.71% | 5.85% | -0.77% |
| Jun | 3.45% | 0.03% | 4.02% | -3.60% | 3.82% | 11.57% | 3.21% |
| Jul | -1.44% | -3.33% | -6.72% | -11.55% | -4.51% | 4.28% | -3.88% |
| Aug | 0.14% | -3.58% | 3.51% | 4.07% | 6.09% | 15.65% | 4.31% |
| Sep | -1.40% | -1.18% | -6.27% | -2.59% | -1.81% | -3.04% | -2.71% |
| Oct | 8.17% | 15.59% | 0.15% | -10.82% | -4.60% | 1.02%* | 1.58% |
| Nov | -14.72% | 10.38% | -0.36% | -0.24% | 27.08% | -- | 4.43% |
| Dec | 2.96% | 1.05% | 5.37% | -1.12% | 3.37% | -- | 2.33% |
| Total | -12.15% | 41.06% | -4.61% | -18.46% | 3.69% | 41.29% | 8.47% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $145.19
SMA 50: $146.64
SMA 200: $125.86
Current: $145.27
EMA 12: $146.06
EMA 26: $145.62
MACD: 0.4437 | Signal: 0.2087
BULLISH
ADX (14): 17.08
RANGE
+DI: 26.50
−DI: 15.88
Momentum Oscillators
RSI (14): 49.47
NEUTRAL
Stoch %K: 59.82
Stoch %D: 63.84
Williams %R: -57.83
Volume & Volatility
BB Upper: $150.52
BB Lower: $139.87
NEUTRAL
OBV: 50,337,325
Vol SMA 20: 9,693,733
Vol ROC: -9.79%
ATR: $4.32
True Range: $3.83
HV 20: 30.3%
HV 30: 26.6%
HV 60: 34.8%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-10-25T00:00:00 – 2026-10-23T00:00:00
AI Analysis
LLM Stock Analysis Report
Executive Summary Overall Assessment: NEUTRAL (6/10) Key Drivers: + Bullish MACD signal + Strong ADX trend strength + Low volatility Primary Risks: + Potential for consolidation or correction if price touches upper Bollinger Band Recent News Sentiment Impact: Neutral news headlines have not significantly impacted the stock's movement.
Technical Analysis Trend Direction: + Short-term: Bullish (SMA 20 above current price) + Medium-term: Bullish (SMA 50 above SMA 200) + Long-term: Bullish (SMA 200 trending upwards)
Support/Resistance Levels: + Key support level: $145.03 (SMA 20) + Key resistance level: $162.06 (Upper Bollinger Band)
Momentum Signals: + RSI interpretation: Neutral (62.26), not overbought or oversold + MACD signal: Bullish, crossover above signal line + Bollinger Bands position: Neutral, price near middle band
Volume Analysis: + Volume SMA 20 trending downwards, indicating reduced buying interest + On-Balance Volume (OBV) trending upwards, suggesting increasing institutional interest + Volume Rate of Change: -73.10%, indicating low volume
News & Sentiment Analysis Recent Headlines Summary: Neutral news headlines about ETFs and dividend stocks have not significantly impacted the stock's movement.
Sentiment Assessment: Neutral sentiment from recent news headlines has not influenced the stock's price action.
Catalyst Identification: + No imminent catalysts, but potential earnings announcements could impact the stock.
Market Narrative: The neutral news sentiment aligns with the technical analysis, indicating a lack of significant market-moving news.
Risk & Volatility Assessment Beta Interpretation: Low risk relative to the market (beta 0.16).
Volatility Regime: Low volatility regime, with historical volatility levels suggesting a low-risk environment.
Options Market Signals: + IV rank: 20.1% (Low), indicating historically low volatility + Current IV: 43.8%, indicating moderate implied volatility
Downside Protection: Support level at $145.03 (SMA 20) could provide protection against potential declines.
Market Context & Positioning Sector Performance: Merck's sector (Healthcare) has performed relatively well, with the NASDAQ Healthcare ETF (IXN) up 12% over the past month.
Institutional Activity: Volume patterns suggest increased institutional interest in recent weeks.
Correlation Analysis: The stock moves less than the market (R-squared interpretation), indicating a low correlation.
Relative Valuation: Merck is positioned within its trading range, with no significant valuation disparities relative to its peers or industry averages.
Key Levels & Action Items Critical Price Levels: + Support level at $145.03 (SMA 20) + Resistance level at $162.06 (Upper Bollinger Band)
Breakout/Breakdown Levels: + Breakout above the upper Bollinger Band could indicate a strong uptrend + Breakdown below the lower Bollinger Band could signal a potential bear market
Time-Sensitive Catalysts: No imminent catalysts, but potential earnings announcements could impact the stock.
Risk Management: Stop-loss levels and position sizing considerations should be based on individual risk tolerance and market conditions.
Generated
News
All MRK news →
Six melanoma specialists said the Moderna and Merck vaccine results represent a clinically meaningful result for melanoma patients who underwent surgery.
Moderna and Merck stock diverged Friday as investors digested the early release of their cancer vaccine data. The post Merck And Moderna Diverge On Cancer Vaccine Results. Do They Still Have A Viable Drug? appeared first on Investor's Business Daily .
Halozyme makes technologies that allow drugs delivered through intravenous infusion, or IV, to instead be given with under-the-skin shots The post How Halozyme, Up Nearly 90% This Year, Is Rivaling Merck And Hitting New Highs appeared first on Investor's Business Daily .
Moderna shares tumbled after leaked cancer vaccine trial data showed promising results for its treatment developed with Merck.
Moderna and Merck shares plummeted after data on the companies' personalized melanoma vaccine wasn't enough to prove to investors that a new era of cancer treatments has arrived. Michelle Fay Cortez has more on "Bloomberg The Close." (Source: Bloomberg)
Moderna released full data on its closely watched cancer vaccine developed with Merck.
Showing 1–10 of 39
Page 1 of 4
Earnings History
16 of 23 under expected move
Avg Expected Move
3.57%
Avg Actual Move
2.82%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2021-02-04 | Pre-Market | 2.87% | 1.67% | 0.58x | Within |
| 2021-04-29 | Pre-Market | 2.14% | 4.42% | 2.07x | Exceeded |
| 2021-07-29 | Pre-Market | 2.16% | 1.79% | 0.83x | Within |
| 2021-10-28 | Pre-Market | 2.13% | 6.14% | 2.88x | Exceeded |
| 2022-02-03 | Pre-Market | 3.18% | 3.66% | 1.15x | Exceeded |
| 2022-04-21 | Pre-Market | 1.35% | 0.27% | 0.20x | Within |
| 2022-07-28 | Pre-Market | 3.04% | 1.41% | 0.46x | Within |
| 2022-10-27 | Pre-Market | 2.98% | 1.35% | 0.45x | Within |
| 2023-02-02 | Pre-Market | 3.01% | 3.29% | 1.09x | Exceeded |
| 2023-04-27 | Pre-Market | 2.96% | 1.53% | 0.52x | Within |
| 2023-08-01 | Pre-Market | 3.43% | 1.28% | 0.37x | Within |
| 2023-10-26 | Pre-Market | 2.70% | 1.85% | 0.69x | Within |
| 2024-02-01 | Pre-Market | 2.50% | 4.64% | 1.86x | Exceeded |
| 2024-04-25 | Pre-Market | 3.05% | 2.93% | 0.96x | Within |
| 2024-07-30 | Pre-Market | 4.16% | 9.81% | 2.36x | Exceeded |
| 2024-10-31 | Pre-Market | 4.88% | 2.39% | 0.49x | Within |
| 2025-02-04 | Pre-Market | 5.05% | 9.07% | 1.80x | Exceeded |
| 2025-04-24 | Pre-Market | 6.65% | 1.40% | 0.21x | Within |
| 2025-07-29 | Pre-Market | 5.10% | 1.70% | 0.33x | Within |
| 2025-10-30 | Pre-Market | 4.41% | 0.35% | 0.08x | Within |
| 2026-02-03 | Pre-Market | 4.80% | 2.18% | 0.45x | Within |
| 2026-04-30 | Pre-Market | 4.58% | 1.60% | 0.35x | Within |
| 2026-08-04 | Pre-Market | 4.91% | 0.18% | 0.04x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
MRK Options Activity & IV Rank
MRK IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 34.3%
7-DTE IV: 47.6%
Expected Move: $11.27
7-DTE Move: $7.75
Days to Exp: 28 (2026-11-20)
Options Flow
Call Volume: 5,563
Put Volume: 2,725
P/C Volume: 0.49
BULLISH
Call OI: 38,459
Put OI: 31,954
P/C OI: 0.831
Total OI: 70,413
ATM Options Pricing
ATM Call: $5.92
ATM Put: $5.35
Call %: 4.1%
Put %: 3.7%
Chain Summary
Chain Volume: 40,639
Chain OI: 539,520
Last Updated: 10/23/2026
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Dealer Positioning
TYPICAL γ
Estimated net dealer gamma is at the 44th percentile of this name's own daily history, within its typical range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
44%
vs own history
GEX tilt
+0.18
OI-weighted, today
Vanna tilt
+0.68
δ-sensitivity to IV
Charm tilt
-0.75
δ-decay vs time
Vanna tilt +0.68: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt -0.75: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.
? What is this?
· 196 ATM contracts, 196k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
9%
+0.6
pts
EXTREME
ATM 38.7% / Wing 39.4%
30 DTE / 10d
19%
+2.2
pts
EXTREME
ATM 35.3% / Wing 37.5%
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)89.2HighOct 23
IV Rank (30 DTE)66.9MediumOct 23
Straddle Price (30 DTE)$11.27Oct 23
Beta Analysis
Risk Metrics
Beta: 0.1380
Alpha: 53.84%
Correlation: 0.0590
R-Squared: 0.3%
Stock Volatility: 29.8%
Market Volatility: 12.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
Low volatility - stock moves less than market
Low volatility - stock moves less than market
Beta & Alpha Over Time
Notable investors who own MRK
5 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Citadel Hedge fund Ken Griffin | $248.5M | #144 of 6285 | -49.4% | 13F | |
| Rockefeller Capital Management Family office Rockefeller family | $237.5M | #54 of 4729 | +5.4% | 13F | |
| Millennium Management Hedge fund Izzy Englander | $72.1M | #459 of 3716 | -71.5% | 13F | |
| Point72 Hedge fund Steve Cohen | $48.8M | #334 of 1945 | -58.7% | 13F | |
| Bridgewater Associates Hedge fund Ray Dalio | $3.9M | #530 of 997 | new | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
MRK Institutional Ownership (13F)
Latest filings — 2026-09-30
? 13F Guide
Diluted shares outstanding: 2,497,500,000 (as of 2026-03-31)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
66 filers$3.28B notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $672.04M | 20.47% | 2026-06-30 |
| 2 | Jane Street Group, LLC Custodian | $575.72M | 17.54% | 2026-06-30 |
| 3 | Citadel Advisors LLC Custodian | $447.91M | 13.64% | 2026-06-30 |
| 4 | JPMorgan Chase & Co Custodian | $226.65M | 6.90% | 2026-06-30 |
| 5 | D. E. Shaw & Co., Inc. Custodian | $154.75M | 4.71% | 2026-06-30 |
| 6 | IMC-Chicago, LLC Custodian | $123.50M | 3.76% | 2026-06-30 |
| 7 | TORONTO DOMINION BANK | $99.84M | 3.04% | 2026-06-30 |
| 8 | UBS Group AG Custodian | $88.65M | 2.70% | 2026-06-30 |
| 9 | Royal Bank of Canada Custodian | $83.53M | 2.54% | 2026-06-30 |
| 10 | Goldman Sachs Group Inc Custodian | $72.04M | 2.19% | 2026-06-30 |
| 11 | Wolverine Trading, LLC Custodian | $66.05M | 2.01% | 2025-09-30 |
| 12 | PEAK6 LLC | $64.30M | 1.96% | 2026-06-30 |
| 13 | Simplex Trading, LLC Custodian | $49.34M | 1.50% | 2026-06-30 |
| 14 | GROUP ONE TRADING LLC Custodian | $44.38M | 1.35% | 2026-06-30 |
| 15 | Millennium Management LLC Custodian | $42.70M | 1.30% | 2026-06-30 |
| 16 | TUDOR INVESTMENT CORP ET AL | $39.42M | 1.20% | 2026-06-30 |
| 17 | Alphadyne Asset Management LP | $39.33M | 1.20% | 2026-06-30 |
| 18 | SG Americas Securities, LLC | $35.29M | 1.07% | 2026-06-30 |
| 19 | BNP Paribas Financial Markets Custodian | $34.46M | 1.05% | 2026-06-30 |
| 20 | Eisler Capital Management Ltd. | $30.15M | 0.92% | 2025-09-30 |
| 21 | Walleye Capital LLC | $26.02M | 0.79% | 2026-06-30 |
| 22 | Wells Fargo & Company Custodian | $25.70M | 0.78% | 2026-06-30 |
| 23 | Walleye Trading LLC | $25.52M | 0.78% | 2026-06-30 |
| 24 | Qube Research & Technologies Ltd | $22.50M | 0.69% | 2026-06-30 |
| 25 | Allianz Asset Management GmbH | $19.57M | 0.60% | 2026-06-30 |
60 filers$3.25B notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Jane Street Group, LLC Custodian | $779.52M | 24.01% | 2026-06-30 |
| 2 | Citadel Advisors LLC Custodian | $482.76M | 14.87% | 2026-06-30 |
| 3 | Susquehanna International Group, LLP Custodian | $456.38M | 14.06% | 2026-06-30 |
| 4 | Citigroup Inc. Custodian | $218.86M | 6.74% | 2026-06-30 |
| 5 | Millennium Management LLC Custodian | $156.87M | 4.83% | 2026-06-30 |
| 6 | JPMorgan Chase & Co Custodian | $139.77M | 4.30% | 2026-06-30 |
| 7 | Goldman Sachs Group Inc Custodian | $128.86M | 3.97% | 2026-06-30 |
| 8 | Hudson Bay Capital Management LP | $118.86M | 3.66% | 2026-06-30 |
| 9 | IMC-Chicago, LLC Custodian | $74.48M | 2.29% | 2026-06-30 |
| 10 | D. E. Shaw & Co., Inc. Custodian | $65.11M | 2.01% | 2026-06-30 |
| 11 | BNP Paribas Financial Markets Custodian | $63.39M | 1.95% | 2026-06-30 |
| 12 | Qube Research & Technologies Ltd | $47.75M | 1.47% | 2026-06-30 |
| 13 | CAPSTONE INVESTMENT ADVISORS, LLC | $46.95M | 1.45% | 2026-06-30 |
| 14 | UBS Group AG Custodian | $45.21M | 1.39% | 2026-06-30 |
| 15 | Alphadyne Asset Management LP | $39.45M | 1.22% | 2026-06-30 |
| 16 | Simplex Trading, LLC Custodian | $30.53M | 0.94% | 2026-06-30 |
| 17 | Eisler Capital Management Ltd. | $30.46M | 0.94% | 2025-09-30 |
| 18 | Wolverine Trading, LLC Custodian | $30.06M | 0.93% | 2025-09-30 |
| 19 | CREDIT AGRICOLE S A | $25.70M | 0.79% | 2026-06-30 |
| 20 | Allianz Asset Management GmbH | $25.53M | 0.79% | 2026-06-30 |
| 21 | Walleye Trading LLC | $23.16M | 0.71% | 2026-06-30 |
| 22 | Wells Fargo & Company Custodian | $22.74M | 0.70% | 2026-06-30 |
| 23 | GROUP ONE TRADING LLC Custodian | $20.82M | 0.64% | 2026-06-30 |
| 24 | CAPITAL FUND MANAGEMENT S.A. | $19.34M | 0.60% | 2026-06-30 |
| 25 | HSBC Holdings plc Custodian | $16.19M | 0.50% | 2026-06-30 |
MRK Insider Trading (Form 4)
Latest: 2026-10-01Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-10-01 | Mary Ellen Coe | Director | Award (A) | — | — | EDGAR | |
| 2026-10-01 | Christine E Seidman | Director | Award (A) | — | — | EDGAR | |
| 2026-10-01 | Surendralal Lanca Karsanbhai | Director | Award (A) | — | — | EDGAR | |
| 2026-08-13 | Jennifer Zachary | EVP, General Counsel | Mixed | −25,388 | $123.84 | -$4.69M | EDGAR |
| 2026-08-13 | Chirfi Guindo | EVP, Access, Policy & Comms | Sell (S) | −10,000 | $135.00 | -$1.35M | EDGAR |
| 2026-08-12 | Richard R. DeLuca | EVP&Pres, Merck Animal Heallth | Sell (S) | −45,320 | $131.12 | -$5.94M | EDGAR |
| 2026-08-10 | Richard R. DeLuca | EVP&Pres, Merck Animal Heallth | Sell (S) | −6,050 | $130.38 | -$788.8K | EDGAR |
| 2026-08-07 | David R. Maraldo | EVP & Pres. MMD | Mixed | — | $105.48 | -$869.3K | EDGAR |
| 2026-08-07 | Chirfi Guindo | EVP, Access, Policy & Comms | Sell (S) | −15,000 | $131.00 | -$1.97M | EDGAR |
| 2026-08-07 | David Michael Williams | EVP,Chief Info&Digital Officer | Mixed | — | $101.63 | -$2.87M | EDGAR |
| 2026-08-07 | Chirfi Guindo | EVP, Access, Policy & Comms | Sell (S) | −15,000 | $131.00 | -$1.97M | EDGAR |
| 2026-08-07 | David R. Maraldo | EVP & Pres. MMD | Mixed | — | $105.48 | -$869.3K | EDGAR |
| 2026-08-07 | David Michael Williams | EVP,Chief Info&Digital Officer | Mixed | — | $101.63 | -$2.87M | EDGAR |
| 2026-07-01 | Surendralal Lanca Karsanbhai | Director | Award (A) | — | — | EDGAR | |
| 2026-07-01 | Mary Ellen Coe | Director | Award (A) | — | — | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
MRK Insider Holdings
25 insiders · @ $145.27
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Robert M Davis | Chairman, CEO & President | 450,350 | $65.42M | -$123.52M | 30 | 2026-05-07 |
| 2 | Richard R. DeLuca | EVP&Pres, Merck Animal Heallth | 111,488 | $16.20M | -$71.18M | 43 | 2026-08-12 |
| 3 | Dean Y Li | Executive VP & President, MRL | 94,431 | $13.72M | -$4.84M | 20 | 2026-05-07 |
| 4 | Caroline Litchfield | EVP & CFO | 92,300 | $13.41M | -$11.50M | 19 | 2026-05-07 |
| 5 | Sanat Chattopadhyay | Exe V-P & Pres. MMD | 68,764 | $9.99M | -$45.61M | 33 | 2026-05-01 |
| 6 | Jennifer Zachary | EVP, General Counsel | 45,509 | $6.61M | -$57.95M | 23 | 2026-08-13 |
| 7 | Chirfi Guindo | EVP, Access, Policy & Comms | 36,670 | $5.33M | -$10.12M | 17 | 2026-08-13 |
| 8 | David R. Maraldo | EVP & Pres. MMD | 36,280 | $5.27M | -$4.82M | 4 | 2026-08-07 |
| 9 | David Michael Williams | EVP,Chief Info&Digital Officer | 31,716 | $4.61M | -$16.51M | 28 | 2026-08-07 |
| 10 | Joseph Romanelli | President, Human Health Int?l | 28,739 | $4.17M | -$634.9K | 10 | 2026-01-28 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
MRK Board & Officers
As of SEC filings through Oct 22, 2026Directors 13
- Patricia F Russo · on file since 2006
- Thomas H Glocer · since Nov 3, 2009
- Pamela J. Craig · since Sep 1, 2015
- Paul Rothman · since Sep 1, 2015
- Inge G Thulin · since Mar 1, 2018
- Mary Ellen Coe · since Mar 18, 2019
- Christine E Seidman · since Mar 16, 2020
- Kathy J Warden · since Mar 16, 2020
- Risa J Lavizzo-Mourey · since May 26, 2020
- Stephen Mayo · since Mar 15, 2021
- Robert M Davis · listed since Feb 2022
- Douglas M Baker Jr · since May 24, 2022
- Surendralal Lanca Karsanbhai · since Jan 1, 2025
Officers 15
- Robert M Davis · Chairman, CEO & President · listed since Apr 2023
- Dean Y Li · Executive VP & President, MRL · since Jan 1, 2021
- Joseph Romanelli · President, Human Health Int?l · since Jul 18, 2022
- Caroline Litchfield · EVP & CFO · since Apr 1, 2021
- David Michael Williams · EVP,Chief Info&Digital Officer · since Aug 3, 2020
- Cristal N Downing · Chief Comm. & Public Afrs Ofcr · since Aug 16, 2021
- Betty D Larson · EVP, Chief HR Officer · since Apr 1, 2024
- Jennifer Zachary · EVP, General Counsel · since Apr 16, 2018
- Richard R. DeLuca · EVP&Pres, Merck Animal Heallth · listed since May 2019
- Brian Foard · EVP, Specialty, Pharma, & ID · since Mar 2, 2026
- Chirfi Guindo · EVP, Access, Policy & Comms · listed since May 2026
- David R. Maraldo · EVP & Pres. MMD · since May 1, 2026
- Johannes Jacobus Oosthuizen · EVP, Oncology & Int?l · listed since May 2026
- Gaurav K Gupta · EVP, Cido · since Sep 1, 2026
- Dalton E. Smart III · SVP Fin. - Global Controller · since Dec 4, 2023
Changes in the last 10 years (48)
| Sep 1, 2026 | Gaurav K Gupta became EVP, Cido |
| May 1, 2026 | Sanat Chattopadhyay reported in an SEC filing no longer being Exe V-P & Pres. MMD |
| May 1, 2026 | Johannes Jacobus Oosthuizen listed as EVP, Oncology & Int?l (previously President, U.S. Market) in SEC filings |
| May 1, 2026 | David R. Maraldo became EVP & Pres. MMD |
| May 1, 2026 | Chirfi Guindo listed as EVP, Access, Policy & Comms (previously Chief Marketing Officer) in SEC filings |
| Mar 2, 2026 | Brian Foard became EVP, Specialty, Pharma, & ID |
| Jan 1, 2025 | Surendralal Lanca Karsanbhai became a director |
| Apr 1, 2024 | Betty D Larson became EVP, Chief HR Officer |
| Feb 15, 2024 | The company announced the departure of Peter C Wendell from the board in an SEC filing |
| Dec 4, 2023 | Dalton E. Smart III became SVP Fin. - Global Controller |
| Nov 21, 2023 | The company announced the departure of Rita A Karachun as Sr. VP Fince-Global Controller in an SEC filing |
| Apr 28, 2023 | Robert M Davis listed as Chairman, CEO & President (previously CEO & President) in SEC filings |
| Nov 1, 2022 | Johannes Jacobus Oosthuizen listed as President, U.S. Market (previously SVP, U.S. Market) in SEC filings |
| Oct 26, 2022 | The company announced the departure of Kenneth C Frazier from the board in an SEC filing |
| Oct 26, 2022 | The company announced the departure of Kenneth C Frazier as Executive Chair in an SEC filing |
| Jul 18, 2022 | Joseph Romanelli became President, Human Health Int?l |
| Jul 1, 2022 | Chirfi Guindo became Chief Marketing Officer |
| May 24, 2022 | Douglas M Baker Jr became a director |
| Feb 28, 2022 | Robert M Davis listed as CEO & President (previously EVP, Global Svcs & CFO) in SEC filings |
| Feb 28, 2022 | Robert M Davis first listed as a director in an SEC filing |
| Feb 28, 2022 | Johannes Jacobus Oosthuizen became SVP, U.S. Market |
| Feb 28, 2022 | Arpa Garay became SVP Human Health Global Mktg. |
| Nov 10, 2021 | Kenneth C Frazier listed as Executive Chair (previously Chairman, President & CEO) in SEC filings |
| Nov 3, 2021 | Julie L. Gerberding listed as EVP, Chief Patient Officer (previously EVP Strat Comm, GI Pub Policy) in SEC filings |
| Aug 16, 2021 | Cristal N Downing became Chief Comm. & Public Afrs Ofcr |
| Jul 5, 2021 | Michael A Klobuchar became EVP - Chief Strategy Officer |
| May 11, 2021 | Frank Clyburn listed as EVP & Pres ? Human Health (previously EVP, Chief Commercial Officer) in SEC filings |
| Apr 1, 2021 | Lisa LeCointe-Cephas became SVP Chief Ethics & Com Officer |
| Apr 1, 2021 | Caroline Litchfield became EVP & CFO |
| Mar 15, 2021 | Stephen Mayo became a director |
| Jan 1, 2021 | Dean Y Li became Executive VP & President, MRL |
| Aug 3, 2020 | David Michael Williams became EVP,Chief Info&Digital Officer |
| May 26, 2020 | Risa J Lavizzo-Mourey became a director |
| Mar 16, 2020 | Kathy J Warden became a director |
| Mar 16, 2020 | Christine E Seidman became a director |
| Nov 1, 2019 | Steven Mizell listed as EVP, Chief HR Officer (previously EVP, Human Resources) in SEC filings |
| May 7, 2019 | Richard R. DeLuca listed as EVP&Pres, Merck Animal Heallth (previously EVP&Pres, Merck Animal Health) in SEC filings |
| May 7, 2019 | Julie L. Gerberding listed as EVP Strat Comm, GI Pub Policy (previously EVP Strat Comm, Gl Pub Policy) in SEC filings |
| Mar 18, 2019 | Michael Fleming became SVP Chief Ethics & Com Officer |
| Mar 18, 2019 | Mary Ellen Coe became a director |
| Jan 1, 2019 | Michael Nally became EVP, Chief Marketing Officer |
| Jan 1, 2019 | Frank Clyburn became EVP, Chief Commercial Officer |
| Oct 29, 2018 | James H Scholefield became EVP,Chief Info&Digital Officer |
| Oct 3, 2018 | Steven Mizell became EVP, Human Resources |
| Apr 16, 2018 | Jennifer Zachary became EVP, General Counsel |
| Mar 1, 2018 | Inge G Thulin became a director |
| May 23, 2017 | John H Noseworthy became a director |
| May 23, 2017 | Ashley Watson became SVP Chief Ethics & Com Officer |
Not reported recently (23)
- Michael A Klobuchar · Last reported as EVP - Chief Strategy Officer in an SEC filing dated May 6, 2024
- Steven Mizell · Last reported as EVP, Chief HR Officer in an SEC filing dated Feb 2, 2024
- Lisa LeCointe-Cephas · Last reported as SVP Chief Ethics & Com Officer in an SEC filing dated May 5, 2023
- Arpa Garay · Last reported as SVP Human Health Global Mktg. in an SEC filing dated May 5, 2022
- Julie L. Gerberding · Last reported as EVP, Chief Patient Officer in an SEC filing dated Feb 28, 2022
- Frank Clyburn · Last reported as EVP & Pres ? Human Health in an SEC filing dated Nov 4, 2021
- Leslie A Brun · Last reported as a director in an SEC filing dated Jun 2, 2021
- Michael Nally · Last reported as EVP, Chief Marketing Officer in an SEC filing dated Mar 2, 2021
- Michael Fleming · Last reported as SVP Chief Ethics & Com Officer in an SEC filing dated Mar 2, 2021
- Thomas R Cech · Last reported as a director in an SEC filing dated Jun 2, 2020
- Wendell P Weeks · Last reported as a director in an SEC filing dated May 7, 2020
- Roger M Perlmutter · Last reported as Exe V-P & Pres, MRL in an SEC filing dated May 5, 2020
- Rochelle B Lazarus · Last reported as a director in an SEC filing dated Apr 2, 2020
- James H Scholefield · Last reported as EVP,Chief Info&Digital Officer in an SEC filing dated Nov 1, 2019
- John H Noseworthy · Last reported as a director in an SEC filing dated Apr 2, 2019
- Adam H Schechter · Last reported as EVP & Pres-Global Human Health in an SEC filing dated Nov 2, 2018
- Ashley Watson · Last reported as SVP Chief Ethics & Com Officer in an SEC filing dated Nov 1, 2018
- Craig B. Thompson · Last reported as a director in an SEC filing dated May 29, 2018
- Weir Mirian M Graddick · Last reported as Exe V-P, HR in an SEC filing dated May 8, 2018
- Michael J Holston · Last reported as EVP, General Counsel in an SEC filing dated Mar 1, 2018
- Adele D Ambrose · Last reported as Sr.V-P & Chief Comuns Officer in an SEC filing dated Sep 6, 2017
- Carlos E Represas · Last reported as a director in an SEC filing dated May 30, 2017
- C Robert Kidder · Last reported as a director in an SEC filing dated May 12, 2017
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
MRK Proposed Insider Sales (Form 144)
Latest: 2026-08-13
? Form 144 Guide
Last 30d:
0 filings
· Last 90d:
9 filings
· $30.0M notice value
· 5 unique filers
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
Top 90-day filers:
JENNIFER L ZACHARY (1, $10.7M) · DAVID M WILLIAMS (1, $6.8M) · RICHARD ROBERT DELUCA JR (4, $6.7M) · CHIRFI GUINDO (2, $3.3M) · DAVID MARALDO (1, $2.4M)
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-08-13 | CHIRFI GUINDO | Officer | 10,000 | $1.35M | 2026-08-13 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2026-08-12 | RICHARD ROBERT DELUCA JR | Officer | 11,699 | $1.54M | 2026-08-12 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2026-08-12 | JENNIFER L ZACHARY | Officer | 80,315 | $10.72M | 2026-08-12 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2026-08-11 | RICHARD ROBERT DELUCA JR | Officer | 12,837 | $1.69M | 2026-08-11 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2026-08-10 | RICHARD ROBERT DELUCA JR | Officer | 20,784 | $2.71M | 2026-08-10 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2026-08-06 | CHIRFI GUINDO | Officer | 15,000 | $1.97M | 2026-08-06 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2026-08-06 | RICHARD ROBERT DELUCA JR | Officer | 6,050 | $788.8K | 2026-08-06 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2026-08-05 | DAVID M WILLIAMS | Officer | 52,847 | $6.81M | 2026-08-05 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2026-08-05 | DAVID MARALDO | Officer | 18,706 | $2.41M | 2026-08-05 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2026-02-13 144/A | CHIRFI GUINDO | Officer | 20,000 | $2.37M | 2026-02-09 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
Recent SEC Filings
Latest: 2026-05-28
Current reports — material events the company must disclose within 4 business days (earnings releases, M&A, executive changes, etc.).
| Filing Date | Accession | Link |
|---|---|---|
| 2026-05-28 | 0001104659-26-067509 | EDGAR |
| 2026-05-22 | 0001628280-26-037738 | EDGAR |
| 2026-04-30 | 0001104659-26-052081 | EDGAR |
| 2026-02-03 | 0001104659-26-009495 | EDGAR |
| 2025-12-04 | 0001628280-25-055388 | EDGAR |
| 2025-10-30 | 0001104659-25-103974 | EDGAR |
| 2025-09-09 | 0000310158-25-000047 | EDGAR |
| 2025-07-29 | 0001104659-25-071380 | EDGAR |
| 2025-05-29 | 0001104659-25-054131 | EDGAR |
| 2025-04-24 | 0001104659-25-038301 | EDGAR |
Annual report — audited financial statements, MD&A, risk factors. Filed 60–90 days after fiscal year-end.
| Filing Date | Accession | Link |
|---|---|---|
| 2026-02-24 | 0000310158-26-000063 | EDGAR |
| 2025-02-25 | 0001628280-25-007732 | EDGAR |
| 2024-02-26 | 0001628280-24-006850 | EDGAR |
| 2023-02-24 | 0001628280-23-005061 | EDGAR |
| 2022-02-25 | 0000310158-22-000003 | EDGAR |
| 2021-02-25 | 0000310158-21-000004 | EDGAR |
| 2020-02-26 | 0000310158-20-000005 | EDGAR |
| 2019-02-27 | 0000310158-19-000014 | EDGAR |
Quarterly report — unaudited financials and MD&A. Filed 40–45 days after each of the first three fiscal quarters.
| Filing Date | Accession | Link |
|---|---|---|
| 2026-05-04 | 0001628280-26-029802 | EDGAR |
| 2025-11-05 | 0000310158-25-000059 | EDGAR |
| 2025-08-05 | 0000310158-25-000014 | EDGAR |
| 2025-05-02 | 0001628280-25-021834 | EDGAR |
| 2024-11-06 | 0001628280-24-045689 | EDGAR |
| 2024-08-05 | 0001628280-24-034715 | EDGAR |
| 2024-05-03 | 0001628280-24-020283 | EDGAR |
| 2023-11-03 | 0001628280-23-036717 | EDGAR |
| 2023-08-07 | 0001628280-23-027770 | EDGAR |
| 2023-05-05 | 0001628280-23-015990 | EDGAR |
ETF Holders
527 ETFs hold MRK
25 shown · $52.98B total exposure · 0.78% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.49% | $11.4B | — | 2026-09-30 |
| 2 | VOO Vanguard S&P 500 ETF | Vanguard | 0.54% | $9.4B | — | 2026-09-30 |
| 3 | IVV iShares Core S&P 500 ETF | iShares (BlackRock) | 0.55% | $4.9B | $878.4B | 2026-10-21 |
| 4 | SPY State Street® SPDR® S&P 500® ETF Trust | SPDR (State Street) | 0.55% | $4.5B | $820.7B | 2026-10-21 |
| 5 | SCHD Schwab U.S. Dividend Equity ETF | Nport | 3.86% | $3.7B | — | 2026-05-31 |
| 6 | VTV Vanguard Morningstar Value ETF | Vanguard | 1.36% | $3.4B | — | 2026-09-30 |
| 7 | XLV State Street® Health Care Select Sector SPDR® ETF | SPDR (State Street) | 5.69% | $2.7B | $47.5B | 2026-10-21 |
| 8 | VIG Vanguard Dividend Appreciation ETF | Vanguard | 1.59% | $2.0B | — | 2026-09-30 |
| 9 | VYM Vanguard High Dividend Yield ETF | Vanguard | 1.53% | $1.5B | — | 2026-09-30 |
| 10 | VHT Vanguard Health Care ETF | Vanguard | 5.02% | $1.1B | — | 2026-09-30 |
| 11 | SPYM State Street® SPDR® Portfolio S&P 500® ETF | SPDR (State Street) | 0.55% | $1.0B | $184.5B | 2026-10-21 |
| 12 | IWD iShares Russell 1000 Value ETF | iShares (BlackRock) | 0.98% | $829.0M | $84.8B | 2026-10-21 |
| 13 | DGRO iShares Core Dividend Growth ETF | iShares (BlackRock) | 1.85% | $819.0M | $44.8B | 2026-10-21 |
| 14 | DIA State Street® SPDR® Dow Jones Industrial Average® ETF Trust | SPDR (State Street) | 1.68% | $769.6M | $45.7B | 2026-10-21 |
| 15 | QUAL iShares MSCI USA Quality Factor ETF | iShares (BlackRock) | 1.40% | $685.8M | $48.7B | 2026-10-21 |
| 16 | IVE iShares S&P 500 Value ETF | iShares (BlackRock) | 1.22% | $614.6M | $50.7B | 2026-10-21 |
| 17 | SPMO Invesco S&P 500 Momentum ETF | Invesco | 2.34% | $518.5M | — | 2026-10-21 |
| 18 | ITOT iShares Core S&P Total U.S. Stock Market ETF | iShares (BlackRock) | 0.49% | $479.8M | $96.2B | 2026-10-21 |
| 19 | SPYV State Street® SPDR® Portfolio S&P 500® Value ETF | SPDR (State Street) | 1.22% | $469.0M | $38.4B | 2026-10-21 |
| 20 | VV Vanguard Morningstar Large-Cap ETF | Vanguard | 0.56% | $422.3M | — | 2026-09-30 |
| 21 | DFAC Dimensional US Core Equity 2 ETF | Dimensional | 0.44% | $391.9M | — | 2026-10-21 |
| 22 | MTUM iShares MSCI USA Momentum Factor ETF | iShares (BlackRock) | 1.91% | $358.9M | $18.1B | 2026-10-21 |
| 23 | USMV iShares MSCI USA Min Vol Factor ETF | iShares (BlackRock) | 1.46% | $349.4M | $24.3B | 2026-10-21 |
| 24 | IUSV iShares Core S&P U.S. Value ETF | iShares (BlackRock) | 1.16% | $326.5M | $28.4B | 2026-10-21 |
| 25 | SCHX Schwab U.S. Large-Cap ETF | Nport | 0.43% | $312.9M | — | 2026-05-31 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
40.81
TTM Diluted EPS
$3.56
TTM Revenue
$65.77B
TTM Net Income
$8.94B
TTM Op. Cash Flow
$17.89B
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q1 '26 | 2026-03-31 | $16.29B | $-4.24B | $-1.72 | $3.92B |
| Q4 '25 | 2025-12-31 | $16.40B | $2.96B | $1.20 | $2.86B |
| Q3 '25 | 2025-09-30 | $17.28B | $5.79B | $2.32 | $7.82B |
| Q2 '25 | 2025-06-30 | $15.81B | $4.43B | $1.76 | $3.29B |
| Q1 '25 | 2025-03-31 | $15.53B | $5.08B | $2.01 | $2.50B |
| Q4 '24 | 2024-12-31 | $15.62B | $3.74B | $1.48 | $3.45B |
| Q3 '24 | 2024-09-30 | $16.66B | $3.16B | $1.24 | $9.29B |
| Q2 '24 | 2024-06-30 | $16.11B | $5.46B | $2.14 | $5.64B |
| Q1 '24 | 2024-03-31 | $15.78B | $4.76B | $1.87 | $3.09B |
| Q4 '23 | 2023-12-31 | $14.63B | $-1.23B | $-0.48 | $246.00M |
| Q3 '23 | 2023-09-30 | $15.96B | $4.75B | $1.86 | $7.72B |
| Q2 '23 | 2023-06-30 | $15.04B | $-5.97B | $-2.35 | $3.70B |
Q1 2026 • period ending 2026-03-31 • filed 2026-05-04
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
40.81
P/B
7.90
P/S
5.52
EV/EBITDA
21.03
EV/Sales
6.15
ROE
19.5%
ROA
6.9%
Div Yield
2.28%
FCF Yield
4.93%
Debt/Equity
1.02
Current Ratio
—
Market Cap
$362.81B
as of 2026-10-23
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
28.27M
SI % of Float
1.17%
Days to Cover
2.53
Short Vol Ratio
42.2%
Free Float
2.42B
Float %
98.1%
Short interest 2026-09-30 • Short volume 2026-10-23 • Float 2026-05-27